Investigating how lung cancer cells change to resist treatment with KRAS inhibitors
Targeting cell state transitions driving resistance to KRAS inhibitors in lung cancer
This study is looking at how some lung cancer cells change in a way that makes them resistant to new treatments, specifically for patients with lung adenocarcinoma caused by KRAS mutations, and aims to find ways to overcome this resistance to help improve their treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11110407 on NIH RePORTER |
What this research studies
This research focuses on lung adenocarcinoma, a type of lung cancer often driven by KRAS mutations. It aims to understand how certain cancer cells transition into states that resist treatment with newly approved KRAS inhibitors. By using advanced models and patient samples, the researchers will identify specific cell states that contribute to this resistance. The goal is to develop strategies to target these resistant cell states, potentially improving treatment outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lung adenocarcinoma, particularly those with KRAS mutations.
Not a fit: Patients with lung cancer types that do not involve KRAS mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for lung cancer patients by overcoming resistance to current therapies.
How similar studies have performed: Other research has shown promise in targeting cancer cell state transitions, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Wong, Kwok Kin — New York University School of Medicine
- Study coordinator: Wong, Kwok Kin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.